Clinical Trials

Inclusion Criteria:

• Women currently between 45-60 years of age

• Have moderate to severe VMS, defined as 28 or more hot flashes per week (including night sweats) and were sufficient severity to prompt them to seek therapeutic intervention

• Are English-speaking

• Able to participate fully in all aspects of the study

• Have understood and signed study informed consent

• Have access to a computer or smartphone and home Wi-Fi

• Willing to participate in weekly VR sessions for 8 weeks

Exclusion Criteria:

• Women receiving systemic menopause hormonal therapy (progesterone, testosterone, estrogen). Low-dose topical vaginal estrogen is okay;

• Women receiving non-hormonal therapy for the management of hot flashes (fezolinetant or elinzanetant, any SSRI/SNRI, oxybytunin, and/or gabapentin being prescribed for hot flashes, if for other reasons and still with hot flashes then okay);

• Women receiving active cognitive behavioral therapy (CBT) for hot flashes. CBT for mood symptoms is okay;

• Have a known, active, untreated clinically significant psychiatric condition (severe depression, psychosis, bipolar disorder, or severe depression);

• Have severe visual, auditory, or vestibular impairments that may interfere with VR use;

• Have a facial/head deformity that will prohibit the wearing of a VR head mounted displace (HMD);

• Self-reported history of acute and/or severe motion sickness;

• Have had a seizure in the past year;

• Concurrently enrolled in another intervention trial for menopause symptoms;

• Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 03/09/2026. Questions regarding updates should be directed to the study team contact.